Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced equity inducement grants to 8 new employees hired in Q3 2025. The grants, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 49,805 restricted stock units (RSUs). These RSUs will vest over four years, with 25% vesting annually on the grant date anniversary, contingent on continued employment.

The equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Compensation Committee of Sarepta's Board of Directors.

Sarepta Therapeutics (NASDAQ:SRPT) has announced 25 recipients for its Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program, now in its 8th year, will award $5,000 scholarships to 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals with the condition.

The scholarship recipients were selected by an independent committee based on academic records, community involvement, personal essays, and recommendation letters. Since its inception, the program has awarded more than 150 scholarships. The program's name, Route 79, references the 79 exons of the dystrophin gene, which is linked to Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) has announced a significant refinancing of its convertible notes through privately negotiated exchange agreements. The company will exchange approximately $700 million of its 1.25% convertible senior notes due 2027 for new 4.875% convertible notes due 2030 worth $602 million, along with up to 6.7 million shares of common stock and $123.3 million in cash.

The new convertible notes have an initial conversion rate of 16.6667 shares per $1,000 principal amount, equivalent to a conversion price of approximately $60.00 per share, representing a 191.5% premium. Additionally, Sarepta entered into a private placement agreement with J. Wood Capital Advisors LLC for up to 1.4 million shares of common stock. The transactions are expected to close around August 28, 2025.

Sarepta Therapeutics (NASDAQ:SRPT) announced two significant financial transactions related to its siRNA collaboration with Arrowhead Pharmaceuticals. The company has sold 9,265,312 shares of Arrowhead stock in a block trade for $174 million in gross proceeds. Additionally, Sarepta will transfer 2,660,989 shares to Arrowhead to satisfy $50 million of a $100 million milestone payment.

The milestone payment was triggered by positive safety data review and achievement of enrollment targets in the Phase 1/2 study of SRP-1003, an RNAi therapeutic for type 1 myotonic dystrophy (DM1). Preliminary data from this study is expected in second half of 2025.

Sarepta Therapeutics (NASDAQ:SRPT) reported strong Q2 2025 financial results with total revenues of $611.1 million, up 68% year-over-year. The company achieved GAAP net income of $196.9 million and resumed ELEVIDYS shipments for ambulatory Duchenne patients following FDA review.

Key highlights include net product revenues of $513.1 million, a 42% increase year-over-year, and progress on their restructuring plan targeting over $100 million in cost savings through 2025. The company is advancing multiple siRNA programs with clinical readouts expected in 2025-2026 for FSHD, DM1, SCA2, and Huntington's Disease.

The strategic restructuring announced in July 2025 aims to reduce expenses by $400 million annually starting in 2026, positioning the company to repay its 2027 convertible notes while maintaining focus on high-impact programs.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced it will release its second quarter 2025 financial results on Wednesday, August 6, 2025, after the Nasdaq market close. The company has noted that it will not host a conference call to discuss the results, as previously announced on July 16, 2025.

Sarepta maintains leadership positions in Duchenne muscular dystrophy treatments and is expanding its portfolio across muscle, central nervous system, and cardiac diseases.

Sarepta Therapeutics (NASDAQ:SRPT) announced that the FDA has recommended lifting the voluntary pause on ELEVIDYS shipments for ambulatory Duchenne muscular dystrophy patients. The FDA's swift review confirmed that a reported death of an 8-year-old patient in Brazil was unrelated to ELEVIDYS treatment.

The company will immediately resume shipping the gene therapy to treatment sites for ambulatory patients, while shipments for non-ambulatory patients remain paused pending further discussions with the FDA regarding risk-mitigation approaches. Sarepta will continue working with the FDA to complete safety label updates and determine the path forward for non-ambulatory patients.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has achieved a significant milestone in its collaboration with Sarepta Therapeutics (NASDAQ: SRPT), earning a $100 million payment. The milestone was triggered by reaching the first enrollment target in a Phase 1/2 clinical study of ARO-DM1, an RNAi therapeutic targeting type 1 myotonic dystrophy (DM1).

The company anticipates reaching a second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment. The current payment is expected to be received within 60 days, as per the license and collaboration agreement terms.

Sarepta Therapeutics (NASDAQ:SRPT) has issued a clarifying statement regarding a reported death of an eight-year-old Duchenne muscular dystrophy patient who received ELEVIDYS gene therapy. The company emphasized that the death was deemed unrelated to the treatment, as confirmed by both Roche Holding AG and the reporting physician.

The incident was reported to the FDA on June 18, 2025, through the FDA's postmarketing electronic database (FAERS). ELEVIDYS remains the only approved gene therapy for Duchenne muscular dystrophy, indicated for both ambulatory and non-ambulatory patients aged 4 years and above.